Efficacy of venetoclax plus anti-CD38 monoclonal antibody-containing therapies among t(11;14) positive multiple myeloma patients regardless of timing of prior treatment with this antibody

被引：2
作者：
Regidor, Bernard Sean [1 ]
Siddiqi, Dilawer [1 ]
Beatty, Bethany Marie [1 ]
Goldwater, Marissa-Skye [2 ]
Jew, Scott [1 ,2 ]
Bujarski, Sean [1 ,2 ]
Swift, Regina [1 ]
Kim, Susanna
Berenson, James R. R. [1 ,2 ,3 ,4 ]
机构：
[1] Berenson Canc Ctr, West Hollywood, CA USA
[2] Inst Myeloma & Bone Canc Res, West Hollywood, CA USA
[3] Oncotherapeut, West Hollywood, CA USA
[4] Inst Myeloma & Bone Canc Res, 9201 W Sunset Blvd,Ste 300, West Hollywood, CA 90069 USA
来源：
EUROPEAN JOURNAL OF HAEMATOLOGY | 2023年 / 110卷 / 02期
关键词：
anti-CD38; daratumumab; multiple myeloma; venetoclax;
D O I：
10.1111/ejh.13896
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：222 / 223
页数：2
相关论文
共 11 条
  • [1] [Anonymous], 2016, Highlights of prescribing information, Tecentriq (atezolizumab) injection, for intravenous use
  • [2] Phase I Study of Venetoclax Plus Daratumumab and Dexamethasone, With or Without Bortezomib, in Patients With Relapsed or Refractory Multiple Myeloma With and Without t(11;14)
    Bahlis, Nizar J.
    Baz, Rachid
    Harrison, Simon J.
    Quach, Hang
    Ho, Shir-Jing
    Vangsted, Annette Juul
    Plesner, Torben
    Moreau, Philippe
    Gibbs, Simon D.
    Coppola, Sheryl
    Yang, Xiaoqing
    Al Masud, Abdullah
    Ross, Jeremy A.
    Bueno, Orlando
    Kaufman, Jonathan L.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (32) : 3602 - +
  • [3] Current treatment landscape for relapsed and/or refractory multiple myeloma
    Dimopoulos, Meletios A.
    Richardson, Paul G.
    Moreau, Philippe
    Anderson, Kenneth C.
    [J]. NATURE REVIEWS CLINICAL ONCOLOGY, 2015, 12 (01) : 42 - 54
  • [4] Myeloma and the t(11;14)(q13;q32); evidence for a biologically defined unique subset of patients
    Fonseca, R
    Blood, EA
    Oken, MM
    Kyle, RA
    Dewald, GW
    Bailey, RJ
    Van Wier, SA
    Henderson, KJ
    Hoyer, JD
    Harrington, D
    Kay, NE
    Van Ness, B
    Greipp, PR
    [J]. BLOOD, 2002, 99 (10) : 3735 - 3741
  • [5] Efficacy of venetoclax as targeted therapy for relapsed/refractory t(11;14) multiple myeloma
    Kumar, Shaji
    Kaufman, Jonathan L.
    Gasparetto, Cristina
    Mikhael, Joseph
    Vij, Ravi
    Pegourie, Brigitte
    Benboubker, Lofti
    Facon, Thierry
    Amiot, Martine
    Moreau, Philippe
    Punnoose, Elizabeth A.
    Alzate, Stefanie
    Dunbar, Martin
    Xu, Tu
    Agarwal, Suresh K.
    Enschede, Sari Heitner
    Leverson, Joel D.
    Ross, Jeremy A.
    Maciag, Paulo C.
    Verdugo, Maria
    Touzeau, Cyrille
    [J]. BLOOD, 2017, 130 (22) : 2401 - 2409
  • [6] Venetoclax or placebo in combination with bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma (BELLINI): a randomised, double-blind, multicentre, phase 3 trial
    Kumar, Shaji K.
    Harrison, Simon J.
    Cavo, Michele
    de la Rubia, Javier
    Popat, Rakesh
    Gasparetto, Cristina
    Hungria, Vania
    Salwender, Hans
    Suzuki, Kenshi
    Kim, Inho
    Punnoose, Elizabeth A.
    Hong, Wan-Jen
    Freise, Kevin J.
    Yang, Xiaoqing
    Sood, Anjla
    Jalaluddin, Muhammad
    Ross, Jeremy A.
    Ward, James E.
    Maciag, Paulo C.
    Moreau, Philippe
    [J]. LANCET ONCOLOGY, 2020, 21 (12) : 1630 - 1642
  • [7] A phase 2 study of isatuximab monotherapy in patients with multiple myeloma who are refractory to daratumumab
    Mikhael, Joseph
    Belhadj-Merzoug, Karim
    Hulin, Cyrille
    Vincent, Laure
    Moreau, Philippe
    Gasparetto, Cristina
    Pour, Ludek
    Spicka, Ivan
    Vij, Ravi
    Zonder, Jeffrey
    Atanackovic, Djordje
    Gabrail, Nashat
    Martin, Thomas G.
    Perrot, Aurore
    Bensfia, Samira
    Weng, Qilong
    Brillac, Claire
    Semiond, Dorothee
    Mace, Sandrine
    Corzo, Kathryn P.
    Leleu, Xavier
    [J]. BLOOD CANCER JOURNAL, 2021, 11 (05)
  • [8] Treatment options for relapsed and refractory multiple myeloma
    Nooka, Ajay K.
    Kastritis, Efstathios
    Dimopoulos, Meletios A.
    Lonial, Sagar
    [J]. BLOOD, 2015, 125 (20) : 3085 - 3099
  • [9] The Anti-CD38 Antibody Therapy in Multiple Myeloma
    Petrucci, Maria Teresa
    Vozella, Federico
    [J]. CELLS, 2019, 8 (12)
  • [10] Low dose venetoclax in combination with bortezomib, daratumumab, and dexamethasone for the treatment of relapsed/refractory multiple myeloma patients-a single-center retrospective study
    Regidor, Bernard
    Goldwater, Marissa-Skye
    Wang, Jessica
    Bujarski, Sean
    Swift, Regina
    Eades, Benjamin
    Emamy-Sadr, Marsiye
    Eshagian, Shahrooz
    Schwartz, Gary
    Spektor, Tanya M.
    Berenson, James R.
    [J]. ANNALS OF HEMATOLOGY, 2021, 100 (08) : 2061 - 2070
12